Shares of Aurobindo Pharma fell by nearly 4 per cent Friday after the company received a warning letter from the US health regulator for one of its units in Srikakulam district in Andhra Pradesh.
The scrip declined 3.92 per cent to close at Rs 602.35 on the BSE. During the day, it dropped 7.68 per cent to Rs 578.75.
On NSE, shares of the company fell by 3.85 per cent to close at Rs 603.
In terms of traded volume, 4.47 lakh shares of the company changed hands on the BSE and over 74 lakh shares were traded on the NSE during the day.
The company has received a warning letter from the United States Food and Drug Administration (USFDA) relating to our unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam District, Andhra Pradesh.
This action follows the earlier inspection of the site by the USFDA in February 2019, Aurobindo Pharma said in a BSE filing.
Aurobindo Pharma said it "believes the existing business from this facility will not be impacted".
"We will be engaging with the regulator and are fully-committed in resolving this issue at the earliest. The company is also committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe," the company added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app